HC Wainwright Reiterates Neutral Rating for LAVA Therapeutics (NASDAQ:LVTX)

HC Wainwright reissued their neutral rating on shares of LAVA Therapeutics (NASDAQ:LVTX) in a research report released on Thursday, MarketBeat.com reports. The brokerage currently has a $1.50 price objective on the stock, down from their previous price objective of $2.00.

A number of other analysts have also issued reports on the company. JMP Securities reaffirmed a “market perform” rating and issued a $6.00 target price on shares of LAVA Therapeutics in a report on Wednesday, December 11th. Leerink Partnrs lowered LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 12th. Leerink Partners reaffirmed a “market perform” rating and issued a $2.00 target price (down previously from $11.00) on shares of LAVA Therapeutics in a report on Thursday, December 12th. Finally, Citizens Jmp lowered LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 11th. Five analysts have rated the stock with a hold rating, Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $3.17.

LAVA Therapeutics Stock Performance

Shares of NASDAQ LVTX opened at $1.29 on Thursday. The firm has a market cap of $33.91 million, a price-to-earnings ratio of -1.25 and a beta of 0.57. The business’s 50-day simple moving average is $1.00 and its 200-day simple moving average is $1.43. LAVA Therapeutics has a 52 week low of $0.85 and a 52 week high of $6.47.

LAVA Therapeutics (NASDAQ:LVTX) last issued its quarterly earnings data on Tuesday, December 10th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.11). As a group, equities research analysts forecast that LAVA Therapeutics will post -1.13 earnings per share for the current year.

Institutional Trading of LAVA Therapeutics

Several institutional investors have recently modified their holdings of LVTX. Sanofi acquired a new stake in shares of LAVA Therapeutics during the 4th quarter worth approximately $1,825,000. BNP Paribas Financial Markets acquired a new stake in shares of LAVA Therapeutics during the 4th quarter worth approximately $40,000. Finally, Virtu Financial LLC acquired a new stake in shares of LAVA Therapeutics during the 3rd quarter worth approximately $32,000.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.